Bernard Gilly

CEO at BrainEver

View Bernard Gilly Emails (It's free) 10 Emails free

Bernard Gilly's Summary

I’m the co-founder and CEO of BrainEver, a biopharmaceutical company pioneering breakthrough therapies for age-related neurodegenerative diseases such as Charcot disease and Parkinson’s. Our preclinical studies on Charcot disease, which affects 500,000 people worldwide and lacks effective treatments, are highly promising. We are set to initiate clinical trials by 2025. To fund this next stage and obtain accelerated marketing approval by 2027, we have decided to open our capital to those who wish to participate in a unique human and scientific journey through the crowdfunding platform Tudigo. With backing from leading investors such as Bpifrance, Ibionext, and Turenne Capital, BrainEver is now raising €35M, including €5M via Tudigo. Join us and become a shareholder 👉 https://tudigo.typeform.com/brainever My passion for biotech innovation doesn’t stop there. I have spent my entire career driving forward cutting-edge therapeutic solutions for patients, either as the CEO of biotech companies or within life sciences investment funds. In 2015, I founded Ibionext, an investment fund where I still serve as Chairman, to invest in high-potential biotech and medtech companies such as ChronoLife, Prophesee, or T-heart. Before that, I co-founded and was the CEO of Gensight Biologics and co-founded Fovea Pharmaceuticals, sold to Sanofi for €370M. From 2000 to 2005, I was a Partner at Sofinnova Partners, one of the largest life sciences investment funds in Europe. Finally, in 1998, as President and CEO of Transgene, I led this pioneering gene therapy company in Europe to its listing on Euronext and Nasdaq.